NTII - Miscellaneous Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTII - Miscellaneous

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	1/5/2005 8:58:13 PM
	of 1296

2005 - Trial in the UK Nervous System Diseases: Alzheimer's disease Participants 75 participants, (i.e. 15 in each arm of the trial) with diagnosis of Alzheimer's disease (AD) and aged between 55 and 95. Randomised interventions Randomised controlled trial (RCT): A. Cholinesterase inhibitor (ChEi) as usual B. Increased dose of ChEi C. Rivastigmine D. Memantine E. ChEi as usual, plus memantine Sources of funding Avon and Wiltshire Mental Health Partnership NHS Trust Contact name(s) Dr Roger Bullock Address Kingshill Research Centre Victoria Hospital Okus Road City/town Swindon Zip/Postcode SN1 4HZ controlled-trials.com Note:The findings of NICE (have nothing to do with above) will be out in MAY 2005. NICE will determine whether or not Memantine (Ebixa) can be prescribed in the UK and paid for by the government. NTII earns a 1% royalty for any Ebixa sold in the UK.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next